COPD Trial, Recruiting NCT05236062 Sponsor: Dana-Farber Cancer Institute Condition: COPD
Back to Copd

COPD Trial, Recruiting

NCT05236062
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have recently been diagnosed with a complication called GVHD (a condition where donated cells react against the body after a transplant) and have just started taking steroid medication for it for the first time since your transplant
  • You received a stem cell transplant from a donor at Dana-Farber Cancer Institute
  • Your doctor has confirmed it is safe for you to do moderate to vigorous exercise
  • You are able to speak English
  • You currently do less than 60 minutes of organised/structured exercise per week
  • You are willing and able to travel to Dana-Farber Cancer Institute for required study visits
  • You are able to understand and sign a written consent form agreeing to take part

Who may not be able to join:

  • You are planning to be admitted to hospital within the next 13 weeks at the time of joining the study
  • You did not join the study within 14 days of starting your steroid treatment
  • You have a pre-existing condition affecting your muscles, joints, heart, or lungs
  • You have an illness that is not well controlled, such as an active infection, uncontrolled diabetes, high blood pressure, or a thyroid condition
  • You are currently receiving other experimental treatments, or are undergoing chemotherapy, biological therapy, or radiation therapy
  • You have another active cancer
  • You already do more than 60 minutes of organised/structured exercise per week
  • You are unable to travel to Dana-Farber Cancer Institute for the required study visits
  • The study team has concerns that you may not be able to safely follow the study's monitoring requirements (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Christina Dieli-Conwright, Dana-Farber Cancer Institute

Phone: 617-582-8321

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
14 April 2022
Est. completion
9 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Proportion of patients completing the exercise intervention sessions

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov